Helius Medical Technologies, Inc. - Class A Common Stock (HSDT)
Frequently Asked Questions About Helius Medical Technologies, Inc. - Class A Common Stock (HSDT)
Has Helius formed any partnerships or collaborations?
Helius Medical Technologies has formed various collaborations with academic institutions and clinical partners to support its research and development goals. These collaborations help advance the understanding of the PoNS™ device and enhance treatment methodologies through shared expertise and resources.
Has Helius Medical Technologies conducted any clinical trials?
Yes, Helius Medical Technologies has conducted several clinical trials to evaluate the safety and efficacy of the PoNS™ device. These studies have produced promising results, demonstrating improvements in functional outcomes for patients with TBI and supporting the company’s commitment to evidence-based therapy.
How can patients access the PoNS™ device?
Patients interested in the PoNS™ device can access it through their healthcare providers who have been trained in its use. The device is typically used in conjunction with a prescribed therapeutic program focused on rehabilitation exercises tailored to individual patient needs.
How does Helius plan to grow in the future?
Helius Medical Technologies plans to grow by expanding clinical research, increasing the reach of the PoNS™ device, and seeking regulatory approvals in new markets. The company is also focused on enhancing partnerships within the healthcare sector, pursuing innovation in neuromodulation technologies, and ultimately broadening its product offerings.
How does the PoNS™ treatment work?
The PoNS™ treatment combines the use of the PoNS™ device with a specific rehabilitation protocol. When patients apply the electrical stimulation to their tongue, it activates pathways in the brain linked to balance and gait control. The combination of stimulation and exercise helps to train the brain and potentially improve functional outcomes.
Is Helius Medical Technologies publicly traded?
Yes, Helius Medical Technologies, Inc. trades publicly on the Nasdaq stock exchange under the ticker symbol HSDT. As a publicly traded company, it is subject to SEC regulations and provides periodic financial disclosures to its investors.
What are the potential risks of investing in Helius Medical Technologies?
Investing in Helius Medical Technologies, like any biomedical company, carries risks including regulatory approval challenges, market acceptance of new therapies, competition from other treatment options, and financial fluctuations. It is essential for investors to conduct thorough research and understand these risks before making investment decisions.
What clinical evidence supports the use of the PoNS™ device?
Clinical evidence supporting the use of the PoNS™ device includes studies that have documented improvements in symptoms and functional capabilities in patients with TBI. The company has published results from clinical trials demonstrating the potential benefits of using the device as part of a comprehensive rehabilitation program.
What does Helius Medical Technologies, Inc. do?
Helius Medical Technologies, Inc. is a biomedical company focused on developing innovative therapies for neurological diseases and conditions. The company primarily aims to offer non-invasive treatment solutions to help individuals affected by disorders such as traumatic brain injury (TBI) through the application of its proprietary PoNS™ device, which is designed to enhance neurologic function.
What is the company's vision and mission?
Helius Medical Technologies is dedicated to enhancing the quality of life for individuals living with neurological conditions. The company's mission is to innovate in the field of neuromodulation therapy and to develop non-invasive treatment options that restore function and promote neuroplasticity—a key element in recovery from brain injuries.
What is the current status of the PoNS™ device approval?
As of October 2023, the PoNS™ device is approved by the U.S. FDA for use in the treatment of symptoms related to TBI. The company continues to pursue additional regulatory approvals in other regions and is committed to supporting further clinical research to expand its indications.
What is the PoNS™ device?
The PoNS™ (Portable Neuromodulation Stimulator) device is a medical device developed by Helius Medical Technologies that uses electrical stimulation to potentially promote neuroplasticity in the brain. This device is worn in the mouth and delivers mild electrical stimulation to the tongue while a patient engages in specific therapeutic exercises, aiming to improve gait, balance, and cognitive functions for individuals with TBI.
What is the significance of neuroplasticity in Helius's therapies?
Neuroplasticity is the brain's ability to reorganize itself by forming new neural connections. Helius Medical Technologies leverages this principle in its therapies, particularly with the PoNS™ device. By applying targeted stimulation and rehabilitation exercises, the company aims to harness neuroplasticity to help patients regain lost functions and improve their quality of life.
What types of neurological conditions does Helius focus on?
Helius Medical Technologies focuses on neurological conditions primarily related to traumatic brain injuries, including concussion, balance issues, and cognitive impairments. The company's research and development efforts are directed towards creating therapies that improve patient outcomes in these areas.
Where is Helius Medical Technologies headquartered?
Helius Medical Technologies is headquartered in Newtown, Pennsylvania. This location serves as the central facility for the company’s research, development, and administrative operations as it works towards bringing its innovative therapy solutions to market.
Who are the target customers for Helius's products?
Helius Medical Technologies primarily targets patients suffering from chronic symptoms of traumatic brain injury and neurological disorders, along with healthcare providers and rehabilitation facilities that specialize in neurological treatments. The company aims to reach both the personal consumer market and healthcare institutions to facilitate better patient outcomes.
Who founded Helius Medical Technologies?
Helius Medical Technologies was founded by Philip C. (Fil) Anderson and others who recognized the need for innovative therapies to address neurological disorders. The founders aimed to utilize advancements in technology and neuroscience to create effective solutions for patients suffering from brain injuries and related conditions.
Who is on Helius Medical Technologies’ leadership team?
Helius Medical Technologies' leadership team comprises experienced professionals from various fields, including biotechnology, neurology, and business management. The team includes individuals with a proven track record in developing medical technologies and bringing innovative healthcare solutions to market.
What is the current price of Helius Medical Technologies, Inc. - Class A Common Stock?
The current price of Helius Medical Technologies, Inc. - Class A Common Stock is 0.3200
When was Helius Medical Technologies, Inc. - Class A Common Stock last traded?
The last trade of Helius Medical Technologies, Inc. - Class A Common Stock was at 1:49 pm EDT on April 7th, 2025
What is the market capitalization of Helius Medical Technologies, Inc. - Class A Common Stock?
The market capitalization of Helius Medical Technologies, Inc. - Class A Common Stock is 1.19M
How many shares of Helius Medical Technologies, Inc. - Class A Common Stock are outstanding?
Helius Medical Technologies, Inc. - Class A Common Stock has 3.73M shares outstanding.